Evaluating a digital tool for supporting breast cancer patients: a randomized controlled trial protocol (ADAPT)

Emma Lidington, Sophie E McGrath, Jillian Noble, Susannah Stanway, Amanda Lucas, Kabir Mohammed, Winette van der Graaf, Olga Husson, Emma Lidington, Sophie E McGrath, Jillian Noble, Susannah Stanway, Amanda Lucas, Kabir Mohammed, Winette van der Graaf, Olga Husson

Abstract

Background: There are a growing number of mHealth tools for breast cancer patients but a lack of scientific evidence for their effects. Recent studies have shown a mix of positive and negative impacts on users. Here we will assess the impact of OWise Breast Cancer, a mobile application for self-monitoring symptoms and managing care, on the process of self-management.

Methods: This randomized controlled trial with early stage breast cancer patients will assess the effect of OWise use on patient activation at 3 months from diagnosis measured by the PAM-13 questionnaire. We will also assess differences in changes in health-related quality of life, psychological distress, health status, and National Health Service (NHS) health resource utilization over the first year from diagnosis. Participants will be randomly allocated (1:1) to standard care or standard care plus OWise. Participants will complete questionnaires before starting anti-cancer treatment and at 3, 6, and 12 months from diagnosis. Clinical and patient-reported outcome data will be linked to health resource utilization data from Discover, an integrated care record of primary, secondary, and social care in North West London. We will measure contamination in the control group and adjust the sample size to mitigate the dilution of effect estimates. A per-protocol analysis will be conducted as a sensitivity analysis to assess robustness of the primary results.

Discussion: This study aims to generate evidence for the effectiveness of OWise at improving patient activation for women with early-stage breast cancer. The results will show the impact of using the tool at the patient level and the NHS health system level. The outcomes of the study will have implications for the application of OWise across the NHS for breast cancer patients and expansion into other tumor types. Assessing publicly available mHealth tools poses a challenge to trialists due to the risk of contamination. Here we apply various methods to measure, mitigate, and assess the effects of contamination.

Trial registration: The study was registered at clincaltrials.gov (NCT03866655) on 7 March 2019.

Keywords: Breast cancer; Health resource utilization; Health-related quality of life; Patient activation; Patient-reported outcome measures; mHealth.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
The Individual and Family Self-Management Theory
Fig. 2
Fig. 2
Schedule of enrolment and assessments

References

    1. Breast Cancer Statistics. . Accessed 12 Jul 2019.
    1. Laudicella M, Walsh B, Burns E, Smith PC. Cost of care for cancer patients in England: Evidence from population-based patient-level data. Br J Cancer. 2016;114:1286–1292. doi: 10.1038/bjc.2016.77.
    1. National Health Service . Next Steps on the NHS Five Year Forward View. 2017.
    1. Hernandez Silva E, Lawler S, Langbecker D. The effectiveness of mHealth for self-management in improving pain, psychological distress, fatigue, and sleep in cancer survivors: a systematic review. J Cancer Surviv. 2019;13:97–107. doi: 10.1007/s11764-018-0730-8.
    1. Kumar S, Nilsen WJ, Abernethy A, Atienza A, Patrick K, Pavel M, et al. Mobile Health Technology Evaluation: The mHealth Evidence Workshop. Am J Prev Med. 2013;45:228–236. doi: 10.1016/j.amepre.2013.03.017.
    1. Jongerius C, Russo S, Mazzocco K, Pravettoni G. Research-Tested Mobile Apps for Breast Cancer Care: Systematic Review. JMIR mHealth uHealth. 2019;7:e10930. doi: 10.2196/10930.
    1. Hwang H. Electronic wound monitoring after ambulatory breast cancer surgery: Improving patient care and satisfaction using a smart phone app. BCMJ. 2016;58(8):448–453.
    1. Egbring M, Far E, Roos M, Dietrich M, Brauchbar M, Kullak-Ublick GA, et al. A mobile app to stabilize daily functional activity of breast cancer patients in collaboration with the physician: A randomized controlled clinical trial. J Med Internet Res. 2016;18:e238. doi: 10.2196/jmir.6414.
    1. Zhu J, Ebert L, Liu X, Wei D, Chan SWC. Mobile breast cancer e-support program for Chinese women with breast cancer undergoing chemotherapy (Part 2): Multicenter randomized controlled trial. JMIR mHealth uHealth. 2018;6:e104. doi: 10.2196/mhealth.9438.
    1. Foley NM, O’Connell EP, Lehane EA, Livingstone V, Maher B, Kaimkhani S, et al. PATI: Patient accessed tailored information: A pilot study to evaluate the effect on preoperative breast cancer patients of information delivered via a mobile application. Breast. 2016;30:54–58. doi: 10.1016/j.breast.2016.08.012.
    1. OWise Breast Cancer. . Accessed 6 Jun 2019.
    1. NHS Apps Library . . Accessed 16 Jul 2019.
    1. Whittaker R, Merry S, Dorey E, Maddison R. A development and evaluation process for mHealth interventions: Examples from New Zealand. J Health Commun. 2012;17:11–21. doi: 10.1080/10810730.2011.649103.
    1. Young-Afat DA, van Gils CH, Bruinvels DJ, van der Pol CC, Witkamp AJ, Sijtsema S, et al. Patients’ and Health Care Providers’ Opinions on a Supportive Health App During Breast Cancer Treatment: A Qualitative Evaluation. JMIR Cancer. 2016;2:e8. doi: 10.2196/cancer.5334.
    1. Polly R, Sawin K. The Individual and Family Self-management Theory: Background and Perspectives on Context, Process, and Outcomes. Nurs Outlook. 2009;57:217–225. doi: 10.1016/j.outlook.2008.10.004.
    1. Greene J, Hibbard JH. Why Does Patient Activation Matter? An Examination of the Relationships Between Patient Activation and Health-Related Outcomes. J Gen Intern Med. 2011;27:520–526. doi: 10.1007/s11606-011-1931-2.
    1. Mitchell SE, Gardiner PM, Sadikova E, Martin JM, Jack BW, Hibbard JH, et al. Patient Activation and 30-Day Post-Discharge Hospital Utilization. J Gen Intern Med. 2013;29:349–355. doi: 10.1007/s11606-013-2647-2.
    1. Hibbard JH, Greene J, Overton V. Patients With Lower Activation Associated With Higher Costs; Delivery Systems Should Know Their Patients’ “Scores”. Health Aff. 2013;2:216–222. doi: 10.1377/hlthaff.2012.1064.
    1. Schulz KF, Grimes DA. Unequal group sizes in randomized trials: guarding against guessing. Lancet. 2002;359:966–970. doi: 10.1016/S0140-6736(02)08029-7.
    1. Kabisch M, Ruckes C, Sibert-Grafe M, Blettner M. Randomized Controlled Trials. Dtsch Arztebl Int. 2011;108(39):663–668.
    1. The Office of Communications . Adults’ media use and attitudes. The Office of Communications. 2017.
    1. Bernat JK, Coa K, Blanch-Hartigan D. Cancer survivors as activated patients: Exploring the relationship between cancer history and patient activation. J Psychosoc Oncol. 2017;35:239–247. doi: 10.1080/07347332.2016.1265624.
    1. Hibbard JH, Stockard J, Mahoney ER, Tusler M. Development of the Patient Activation Measure (PAM): Conceptualizing and Measuring Activation in Patients and Consumers. Health Serv Res. 2004;39:1005–1026. doi: 10.1111/j.1475-6773.2004.00269.x.
    1. Hibbard JH, Mahoney ER, Stock R, Tusler M. Do increases in patient activation result in improved self-management behaviors? Health Serv Res. 2007;42:1443–1463. doi: 10.1111/j.1475-6773.2006.00669.x.
    1. Insigina Health. Patient activation measure (PAM) 13 TM Licence Materials copyright: LLC. Eugene: Insignia Health; 2011.
    1. Morrison D, Wyke S, Saunderson K, Mcconnachie A, Agur K, Chaudhuri R, et al. Findings from a pilot Randomised trial of an Asthma Internet Self-management Intervention (RAISIN) BMJ Open. 2016;6:e009254. doi: 10.1136/bmjopen-2015-009254.
    1. Bakitas M, Lyons KD, Hegel MT, Bakitas M. Effects of a Palliative Care Intervention. JAMA. 2009;302:741–749. doi: 10.1001/jama.2009.1198.
    1. Roberts N, Kidd L, Dougall N, Patel I, McNarry S, Nixon C. Measuring patient activation: the utility of the Patient Activation Measure within a UK context - results from four exemplar studies and potential future applications. Patient Educ Couns. 2016;99:1739–1746. doi: 10.1016/j.pec.2016.05.006.
    1. Hibbard JH, Mahoney ER, Stockard J, Tusler M. Development and testing of a short form of the patient activation measure. Health Serv Res. 2005;40:1918–1930. doi: 10.1111/j.1475-6773.2005.00438.x.
    1. Hibbard J, Helen G. Supporting people to manage their health: an introduction to patient activation, vol. 51. London: King’s Fund; 2014.
    1. Jansen F, Coupé VMH, Eerenstein SEJ, Leemans CR, Verdonck-de Leeuw IM. Costs from a healthcare and societal perspective among cancer patients after total laryngectomy: are they related to patient activation? Support Care Cancer. 2018;26:1221–1231. doi: 10.1007/s00520-017-3945-8.
    1. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–376. doi: 10.1093/jnci/85.5.365.
    1. Bjelic-Radisic V, Bottomley A, Cardoso F, Cameron D, Brain E, Kuljanic K, et al. An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients (EORTC QLQ-BC23) - EORTC QLQ-BR45. Ann Oncol. 2018;29:mdy270–mdy267. doi: 10.1093/annonc/mdy270.267.
    1. Fayers PM, Aaronson NK, Bjordal K, Curran D, Grønvold M. EORTC QLQ-C30 scoring manual. Brussels: EORTC; 1999.
    1. Cocks K, King MT, Velikova G, St-James MM, Fayers PM, Brown JM. Evidence-based guidelines for determination of sample size and interpretation of the European organisation for the research and treatment of cancer quality of life questionnaire core 30. J Clin Oncol. 2011;29:89–96. doi: 10.1200/JCO.2010.28.0107.
    1. Hopwood P, Haviland J, Mills J, Sumo G, M Bliss J. The impact of age and clinical factors on quality of life in early breast cancer: An analysis of 2208 women recruited to the UK START Trial (Standardisation of Breast Radiotherapy Trial) Breast. 2007;16:241–251. doi: 10.1016/j.breast.2006.11.003.
    1. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361–370. doi: 10.1111/j.1600-0447.1983.tb09716.x.
    1. Snaith RP. The Hospital Anxiety And Depression Scale. Health Qual Life Outcomes. 2003;1:29. doi: 10.1186/1477-7525-1-29.
    1. Annunziata MA, Muzzatti B, Altoé G. Defining hospital anxiety and depression scale (HADS) structure by confirmatory factor analysis: A contribution to validation for oncological settings. Ann Oncol. 2011;22:2330–2333. doi: 10.1093/annonc/mdq750.
    1. EuroQol Research Foundation . EQ-5D-5L User Guide. 2019.
    1. Devlin NJ, Shah KK, Feng Y, Mulhern B, van Hout B. Valuing health-related quality of life: An EQ-5D-5L value set for England. Health Econ. 2018;27(1):7–22. doi: 10.1002/hec.3564.
    1. Kimman ML, Dirksen CD, Lambin P, Boersma LJ. Responsiveness of the EQ-5D in breast cancer patients in their first year after treatment. Health Qual Life Outcomes. 2009;7:11. doi: 10.1186/1477-7525-7-11.
    1. Torgerson DJ. Contamination in trials: is cluster randomisation the answer? BMJ. 2001;322:355–357. doi: 10.1136/bmj.322.7282.355.
    1. Van De Poll-Franse LV, Horevoorts N, van Eenbergen M, Denollet J, Roukema JA, Aaronson NK, et al. The Patient Reported Outcomes Following Initial treatment and Long term Evaluation of Survivorship registry: Scope, rationale and design of an infrastructure for the study of physical and psychosocial outcomes in cancer survivorship cohorts. Eur J Cancer. 2011;47:2188–2194. doi: 10.1016/j.ejca.2011.04.034.
    1. Deen D, Lu WH, Rothstein D, Santana L, Gold MR. Asking questions: The effect of a brief intervention in community health centers on patient activation. Patient Educ Couns. 2011;84:257–260. doi: 10.1016/j.pec.2010.07.026.
    1. Shively MJ, Gardetto NJ, Kodiath MF, Kelly A, Smith TL, Stepnowsky C, et al. Effect of patient activation on self-management in patients with heart failure. J Cardiovasc Nurs. 2013;28:20–34. doi: 10.1097/JCN.0b013e318239f9f9.
    1. Murnane A, Gough K, Thompson K, Holland L, Conyers R. Adolescents and young adult cancer survivors: exercise habits, quality of life and physical activity preferences. Support Care Cancer. 2014;23:501–510. doi: 10.1007/s00520-014-2446-2.
    1. Eysenbach G, CONSORT-EHEALTH Group CONSORT-EHEALTH: improving and standardizing evaluation reports of Web-based and mobile health interventions. J Med Internet Res. 2011;13(4):e126. doi: 10.2196/jmir.1923.
    1. Thabane L, Mbuagbaw L, Zhang S, Samaan Z, Marcucci M, Ye C, et al. A tutorial on sensitivity analyses in clinical trials: the what, why, when and how. BMC Med Res Methodol. 2013;13:92. doi: 10.1186/1471-2288-13-92.
    1. McCoy E. Understanding the Intention-to-treat Principle in Randomized Controlled Trials. West J Emerg Med. 2017;18:1075–1078. doi: 10.5811/westjem.2017.8.35985.
    1. Coons SJ, Eremenco S, Lundy JJ, O’Donohoe P, O’Gorman H, Malizia W. Capturing Patient-Reported Outcome (PRO) Data Electronically: The Past, Present, and Promise of ePRO Measurement in Clinical Trials. Patient. 2015;8:301–309. doi: 10.1007/s40271-014-0090-z.
    1. Gwaltney CJ, Shields AL, Shiffman S. Equivalence of electronic and paper-and-pencil administration of patient-reported outcome measures: A meta-analytic review. Value Heal. 2008;11:322–333. doi: 10.1111/j.1524-4733.2007.00231.x.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren